[Efficiency of revaccination against epidemic parotitis and immunological safety]

Seventy-eight children aged 6-7 years were subcutaneously revaccinated with L-3 live mumps vaccine. The vaccine is slightly reactogenic and completely safe. The level of antibodies increased on day 10 postvaccination in 80% of children with initially low antibody titers. Subcutaneous revaccination resulted in appearance of anti-parotitis antibodies in nasal secretions of 60% and in the saliva of 20% children, this indicating sufficiently high immunogenic activity of the vaccine.